{
  "abstract": "Introduction Distinguishing mucinous from non-mucinous pancreatic cysts guides surveillance and surgical decisions. Intracystic glucose ≤2.8 mmol/L is recognised as a useful marker for mucinous cysts, but laboratory turnaround often delays interpretation until after the procedure. If point-of-care testing (POCT) is reliable, clinicians could make earlier decisions and potentially avoid repeat sampling.Methods A retrospective review was performed of patients undergoing EUS-FNA of pancreatic cysts in whom paired intracystic glucose measurements were available from both laboratory assay and bedside glucometer testing. Cyst fluid CEA, cyst morphology and cyst size were recorded where available. Concordance between laboratory and point-of-care glucose measurements was assessed using the clinically relevant ≤2.8 mmol/L cut-off for mucinous cystsResults Eleven patients were included (median age 63 years; range 42–87). Three cysts were classified as mucinous or suspected mucinous, one was malignant, and the remaining were non-mucinous (pseudocysts, simple cyst, serous cystadenoma and one indeterminate non-mucinous lesion). Intracystic glucose measurements demonstrated a high degree of similarity between point-of-care and laboratory testing, with very strong correlation (r=0.95). Using the clinically relevant ≤2.8 mmol/L threshold, diagnostic agreement between Methods was observed in 10 of 11 cases (91%), indicating close concordance for mucinous classification. In this cohort, all mucinous or suspected mucinous cysts demonstrated low intracystic glucose on point-of-care testing, consistent with expected pathophysiology and supported by elevated CEA levels where available. No procedure-related complications were observed.Conclusions Point-of-care intracystic glucose showed close agreement with laboratory glucose and correctly identified all mucinous or suspected mucinous cysts in this pilot group. The ability to obtain cyst glucose immediately during EUS-FNA may help clinicians make earlier decisions around surveillance or surgical referral, without waiting for laboratory results or serum testing. Although numbers are small, these findings support continued prospective data collection to determine whether POCT can reduce diagnostic delay and repeat procedures in routine practice.Abstract P279 Figure 1",
  "authors": [
    {
      "affiliations": [
        "Department of Gastroenterology, East Lancashire Teaching Hospital, Blackburn, United Kingdom"
      ],
      "name": "Mohammed Faraz Ali Khan"
    },
    {
      "affiliations": [
        "Department of Gastroenterology, East Lancashire Teaching Hospital, Blackburn, United Kingdom"
      ],
      "name": "Anas Abou Hatab"
    },
    {
      "affiliations": [
        "Department of Gastroenterology, East Lancashire Teaching Hospital, Blackburn, United Kingdom"
      ],
      "name": "Mohamed Shibeika"
    },
    {
      "affiliations": [
        "Department of Gastroenterology, East Lancashire Teaching Hospital, Blackburn, United Kingdom"
      ],
      "name": "Hassan Hatab"
    },
    {
      "affiliations": [
        "Department of Gastroenterology, East Lancashire Teaching Hospital, Blackburn, United Kingdom"
      ],
      "name": "Venkat Mahesh"
    }
  ],
  "title": "P279 Point-of-care intracystic glucose during EUS-FNA: early experience comparing with laboratory testing",
  "uid": "10aeada1-0423-5ec2-a227-be12543fddb1"
}